Ustekinumab biosimilar(Prestige BioPharma)

乌司奴单抗生物类似药(Prestige BioPharma)

Report date: 2024/10/10 10:04:53

Base Information

Drug NameUstekinumab biosimilar(Prestige BioPharma)
Drug Alias NameIDC2401IDC-2401
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12Interleukin-23
Therapy Area/IndicationsImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active IndicationsImmune System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A